...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.
【24h】

Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.

机译:万古霉素中间性金黄色葡萄球菌导致万古霉素持续输注不能抵抗实验性心内膜炎。

获取原文
获取原文并翻译 | 示例
           

摘要

Continuous infusion of vancomycin was evaluated against experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA. Animals were infected with hVISA PC1 (vancomycin MIC, 2 mg/liter) or VISA PC3 (vancomycin MIC, 8 mg/liter) and treated for 5 days with constant serum levels of 20 or 40 mg/liter. Vancomycin continuous infusion was unsuccessful, as 20 mg/liter was barely active against PC1 (6 of 13 sterile vegetations) and 40 mg/liter failed against PC3 (2 of 9 sterile vegetations).
机译:评估了由于万古霉素中间金黄色葡萄球菌(hVISA)和VISA的异质性,连续输注万古霉素对实验性心内膜炎的作用。用hVISA PC1(万古霉素MIC,2 mg /升)或VISA PC3(万古霉素MIC,8 mg /升)感染动物,并以20或40 mg /升的恒定血清水平处理5天。万古霉素连续输注失败,因为20 mg / L对PC1几乎没有活性(13个无菌植物中的6个),而40 mg / L对PC3无效(9个无菌植物中的2个)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号